Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Stock Chart & Stats
$24.75
-$0.56(-4.53%)
At close: 4:00 PM EST
$24.75
-$0.56(-4.53%)
Day’s Range― - ―
52-Week Range$5.90 - $26.99
Previous CloseN/A
Volume723.92K
Average Volume (3M)6.97M
Market Cap
$2.66B
Enterprise Value$615.77M
Total Cash (Recent Filing)$459.65M
Total Debt (Recent Filing)$102.59M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 06, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding107,346,886
10 Day Avg. Volume7,035,347
30 Day Avg. Volume6,968,650
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue11.65
Enterprise Value/Gross Profit12.91
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$31.81Price Target Upside28.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Market DemandPatients are willing to abandon established therapies to access a potential permanent solution, showing strong commercial demand for Intellia’s treatment.
Product EfficacyNex-z could transform the ATTR-PN treatment paradigm with its best-in-disease efficacy potential.
Research And DevelopmentIntellia has fully enrolled ~60 patients in the pivotal Phase 3 trial of lonvo-z just nine months after first dosing, indicating strong demand for the one-time gene-editing treatment.
Bears Say
Financial PerformanceFinancial results reported—reducing price target.
Product LaunchThe launch of a key product has been delayed based on management commentary.
Stock Price TargetThe price target for the stock has been slightly decreased.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $5.90 and its highest was $26.98 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $2.66B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 16 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.018 by $0.038.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 107,346,886 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.018. Following the earnings report the stock price went up 0.792%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.81 (28.53% Upside)
$31.81 (28.53% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $865.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 17.1%
Last 30 Days ▲ 17.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.96%
12-Months-Change
Fundamentals
Return on Equity
-56.95%
Trailing 12-Months
Asset Growth
-24.56%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA) is a biotechnology company focused on developing transformative therapies using its proprietary CRISPR/Cas9 gene-editing technology. The company operates in the healthcare sector, primarily in the field of genetic medicine, targeting a range of diseases including genetic disorders, cancers, and other serious conditions. Intellia's core products and services revolve around its innovative gene-editing platform, which aims to provide one-time curative treatments by directly addressing the root causes of diseases at the genetic level.
NTLA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong progress in clinical trials and financial stability with accelerated enrollment and positive interim data, balanced by the forthcoming retirement of the CMO and some reported adverse events.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$31.81
▲(28.53% Upside)
Technical Analysis
Xencor
―
Rocket Pharmaceuticals
―
Arvinas Holding Company
―
Vir Biotechnology
―
Nurix Therapeutics
―
Ownership Overview
1.85% Insiders
18.04% Mutual Funds
0.03% Other Institutional Investors
52.21% Public Companies and Individual Investors